Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
THO complex subunit 4 (ALYREF) is a nuclear RNA-binding protein acting as a key mRNA export adapter. It is an integral part of the TREX complex, which couples mRNA transcription, processing, and export from the nucleus[1][4]. ALYREF directly interacts with the nuclear cap binding complex (CBC) via its RNA recognition motif (RRM), facilitating the recruitment of mRNA export machinery to the 5' cap of nascent transcripts[1][2][3]. This step is essential for proper mRNA export and RNA metabolism in eukaryotes. ALYREF also mediates interactions with the export receptor NXF1-NXT1 and is a target for viral proteins that hijack export pathways. Disruption of ALYREF or its interactions, such as by mutations, is associated with various pathologies, including cancer, where it can be upregulated and contribute to disease progression[1][2]. No small molecule drugs are known to target ALYREF as of current literature.
Not applicable for drugs (as no drugs are reported to target ALYREF directly). Viral proteins such as HSV-1 ICP27 and HVS ORF57 interact with the RRM domain of ALYREF to hijack mRNA export machinery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on THO complex subunit 4 (ALYREF).